Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.
暂无分享，去创建一个
C. Town | W. Lumry | H. Farkas | T. Craig | M. Riedl | P. Potter | B. Bloom | A. Reshef | R. Levy | H. Li | D. Moldovan | Hongbin Li | P. C. Potter | H. H. Li | Cape Town | Hongbin Li | Bradley J. Bloom
[1] D. Khan. Hereditary angioedema: Historical aspects, classification, pathophysiology, clinical presentation, and laboratory diagnosis. , 2011, Allergy and asthma proceedings.
[2] J. Nuijens,et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. , 2010, The Journal of allergy and clinical immunology.
[3] William H. Yang,et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. , 2010, The New England journal of medicine.
[4] P. Schlattmann,et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). , 2007, The Journal of allergy and clinical immunology.
[5] J. Levy,et al. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema , 2006, Expert opinion on investigational drugs.
[6] M. Cicardi,et al. Bradykinin and the pathophysiology of angioedema. , 2003, International immunopharmacology.
[7] M. Cicardi,et al. Local bradykinin generation in hereditary angioedema. , 1999, The Journal of allergy and clinical immunology.
[8] F. Petry. Molecular basis of hereditary C1q deficiency. , 1998, Immunobiology.
[9] M. Cicardi,et al. Pathogenetic and clinical aspects of C1 inhibitor deficiency. , 1998, Immunobiology.
[10] M. Cicardi,et al. Plasma bradykinin in angio-oedema , 1998, The Lancet.